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PLANT-BASED DIET TO DELAY THE PROGRESSION OF CHRONIC 
KIDNEY DISEASE 
JUSTIN KOEHL 
ABSTRACT 
Background  
Chronic kidney disease is an insidious, long-term disease, characterized by progressive 
decline in kidney function over time. It currently affects millions of Americans, and 
millions more are at risk to develop the disease in the future. There is no cure-all 
treatment for chronic kidney disease. Current management involves slowing the 
progression in the decline of kidney function, managing associated comorbidities that 
contribute to the disease, including hypertension and type 2 diabetes mellitus, and 
treating disease complications. The overall goal of treatment is to delay the time to 
dialysis and reduce the risk of cardiovascular events. Current management also involves a 
set of dietary restrictions. 
Literature review 
Studies that have been conducted using the current dietary recommendations have been 
shown to have some benefit. However, other studies have demonstrated no advantage 
using these dietary guidelines. Few studies have looked at how the source of food affects 
renal function over time. A review of the literature will highlight the importance of the 
source of food consumption for patients with chronic kidney disease.  
Proposed project 
  vi 
The study being proposed is a randomized-controlled trial comparing current dietary 
recommendations with a plant-based diet for patients with chronic kidney disease. The 
study participants will have a baseline assessment of renal function with follow-up 
throughout. The trial will last for 36 months. The primary outcome being measured is the 
change in estimated glomerular filtration rate over time with secondary outcomes being 
urinary albumin levels, serum bicarbonate, and serum phosphorus.  
Conclusion 
The data from this trial will help conclude if a plant-based diet is more effective than a 
traditionally recommended diet at delaying the decline in glomerular filtration rate for 
patients with chronic kidney disease. 
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INTRODUCTION 
Background 
Chronic kidney disease, or CKD, is a disease characterized by a gradual loss in kidney 
function over time. This includes a spectrum of different disease mechanisms that 
damage the kidneys, resulting in a decreased ability for the kidneys to perform their 
normal physiological functions. Millions of Americans currently have chronic kidney 
disease, while millions more are at an increased risk to develop this condition in time. 
Chronic kidney disease can have a wide range of presentations and courses. There are 
patients who have stable disease, characterized by a slow progression in loss of kidney 
function with few complications of the disease, while other patients may decline at a 
much faster rate and experience several complications. As the disease course reaches its 
end it becomes known as end-stage renal disease, in which renal replacement therapy or 
dialysis are the end line treatments. 
 Because so many Americans are affected by this disease, early detection is key. 
This will allow the disease to be managed timely, in hopes of slowing the decline in 
kidney function. Current treatment and management is very complex. Controlling 
comorbidities associated with CKD, such as hypertension and diabetes, is critical for 
management. As the disease progresses, treating complications are crucial for both 
quality of life and survival for these patients. Treatment involves both medications and 
lifestyle modifications, including diet and physical activity. With early detection and 
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regular follow-up, CKD can be managed properly, thus preserving kidney function for a 
longer period of time. 
 Due to the insidious and progressive nature of CKD, lifestyle modifications is 
particularly important for management, specifically diet. Diet has been demonstrated to 
be a target for potentially slowing the decline in kidney function, reducing kidney injury, 
and managing disease complications, all while having a positive impact on associated 
comorbidities. Current dietary recommendations are moderate protein intake, salt 
restriction, and specific electrolyte target goals guided by lab values. The overall goal of 
dietary management is provide enough nutritional value to maintain a healthy weight and 
muscles mass and provide enough energy for daily living, while avoiding the buildup of 
metabolic wastes and further cause of injury.    
 
Statement of the Problem 
Because millions of Americans are affected by CKD and millions more are at risk, the 
burden of CKD on public healthcare costs is very high. There is no cure-all for CKD, 
which means once a patient is diagnosed they need to be treated and managed for a 
lifetime. This makes dietary modification vital for management. While some diets have 
shown promise in slowing chronic kidney disease decline, no diet has been established as 
the optimal diet. Clinical trials have shown conflicting evidence when comparing certain 
dietary patterns, making it not entirely certain what the most advantageous diet is.   
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 With proper and optimal dietary management patients would have improved 
quality of life, less disease complications, and potentially a slower progression in the 
decline of renal function. This would not only prolong life, but could also null the amount 
of medications people need to take, while delaying the need for renal replacement therapy 
or dialysis. Furthermore, better dietary management may also treat associated 
comorbidities and risk factors of CKD, which may further help protect the kidneys from 
more decline in function.   
 
Hypothesis 
A whole-food, plant-based diet consisting of fruits, vegetables, whole grains, and 
legumes will preserve or slow the progression of chronic kidney disease compared to a 
traditionally recommended diet. 
 
Objectives and specific aims 
The implementation of a plant-based diet will slow the progression of chronic kidney 
disease while improving disease complications. This would give patients a better quality 
of life, decrease mortality, and delay the need for end-stage treatment options such as 
renal transplant surgery or dialysis. A plant-based diet will also provide this patient 
population with sufficient nutritional value that will allow them to maintain a healthy 
weight and have enough energy to carry out daily living.    
 4 
 
1. Compare a plant-based diet with other diets to assess its overall affect on delaying 
or preserving the progression of chronic kidney disease 
2. Demonstrate the ability of a plant-based diet to treat other disease complications 
compared to current dietary or therapeutic recommendations.  
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REVIEW OF THE LITERATURE 
Overview 
What is chronic kidney disease? 
Chronic kidney disease includes a spectrum of different pathophysiological mechanisms 
that leads to impaired kidney function and a progressive decline in the glomerular 
filtration rate. CKD is defined as the presence of kidney damage or decreased kidney 
function for more than 3 months, regardless of the underlying cause. Kidney damage can 
be detected as a urinary albumin excretion ≥ 30mg/day, while decreased kidney function 
is assessed by an estimated glomerular filtration rate of <60 mL/min/1.73m
2
. The role of 
eGFR and urine albumin will be discussed below. The NKF-KDOQI and KDIGO have 
both developed a classification system based on eGFR and albuminuria that stratifies 
patients to guide management and predict risk of progression and complications. 
Table 1. CKD Classification based on eGFR. 
1
 
GFR Stages  GFR (mL/min/1.73m
2
) Terms 
G1 ≥90 Normal or high 
G2 60-89 Mildly decreased  
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased  
G5(D) <15 Kidney failure (add D if treated by dialysis) 
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Table 2. CKD Classification based on Albuminuria.
2
 
Albuminuria Stages AER (mg/day) ACR (mg/g) Terms 
A1 <30 <30 Normal to mildly increased 
A2 30-300 30-300 Moderately increased 
A3 >300 >300 Severely increased 
 
 As the above classification systems suggest, chronic kidney disease is a lasting, 
progressive disease. The pace at which the disease progresses varies from individual to 
individual. Some patients may live their entire lives asymptomatic with a stable GFR, 
while others may decline more rapidly and have several disease complications. As the 
disease course reaches its final stage, it becomes known as end-stage renal disease. It is at 
this stage when considerations are made for dialysis or renal replacement transplant 
therapy. While there is no cure for CKD, proper lifestyle modifications, management, and 
treatment can aid in a slower progression, and in some cases even prevent it. 
 
Epidemiology of chronic kidney disease 
According to the National Kidney Foundation, it is estimated that 26 million Americans 
have CKD, with millions more being at an increased risk to develop the disease.
3
 The 
2016 USRDS Annual Data Report shows that the prevalence of CKD among participants 
in the Health and Nutrition Examination Survey is currently at 14.8%.
4
 Among the 
patient population with a known diagnosis of CKD, stage 3 represents the most prevalent 
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stage of disease course in regards to GFR, while an ACR of <10 mg/g is the most 
prevalent distribution of albuminuria.
4
 CKD occurs most in individuals > 60 years of age 
(32.6%), and affects females (16.5%) more than males (13.0%).
4
 However, males 
comprise 57.3% of all patients receiving treatment for chronic kidney disease compared 
to women at 42.7%. More males are also on dialysis or living with a functioning kidney 
transplant when compared to women.
5
 Among race, African-Americans have the highest 
prevalence of CKD (16.9%), while Non-Hispanic Whites have the second highest at 
(15.2%).
4
  
 Chronic kidney disease has several known risk factors which are clinically 
relevant for both screening and early detection of the disease. Risk factors include 
increasing age, presence of diabetes mellitus, hypertension, cardiovascular disease, 
metabolic syndrome, increased body mass index, family history of end-stage renal 
disease or chronic kidney disease, and a history of acute kidney injury. It is estimated that 
40% of individuals with CKD have diabetes, 32% have hypertension, and 40% have self-
reported cardiovascular disease.
4
 The role of these comorbidities will be discussed in 
more detail below. 
 
Pathophysiology of chronic kidney disease 
Chronic kidney disease can be the result of several different pathophysiological 
mechanisms. While each disease process may be different, the end result is always 
abnormal kidney function or a decline in the filtering ability of the kidney. The two 
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leading causes of CKD are diabetes mellitus and hypertension. CKD that results from 
diabetes is known as diabetic glomerular disease or diabetic nephropathy. CKD resulting 
from hypertension is known as hypertensive nephropathy, and can be either a primary 
glomerulopathy with hypertension or vascular and ischemic renal disease. Other less 
common causes of CKD include a group of diseases collectively known as 
glomerulonephritis, autosomal dominant polycystic kidney disease, and other cystic and 
tubulointerstitial nephropathies. While the underlying cause of CKD may be different, 
there are two basic maladaptive mechanisms that occur resulting in kidney  damage. 
 The first mechanism that occurs is specific to the underlying etiology of the cause 
of CKD. This could be due to inflammation, immune complex deposition, uncontrolled 
blood glucose levels, hypertension, or even genetically smaller kidneys. Regardless of the 
etiology, this results in nephron loss. The second mechanism that occurs is irrespective to 
the underlying cause of nephron loss and kidney damage. Initially these changes are 
adaptive, as the remaining nephrons undergo a process of hyperfiltration and hypertrophy 
which helps preserve glomerular filtration rate. However, over time these changes have 
an overall negative effect on kidney function. The increased pressures and flow to the 
kidney result in structural changes, resulting in further nephron loss and sclerosis of 
kidney tissue. The renin-angiotensin system plays a major role in the development and 
progression of these changes.
6
 This process can take years, which explains the slow 
progression and insidious nature of the disease course. 
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 Because diabetes mellitus and hypertension are the two leading causes of chronic 
kidney disease, and due to the fact that these underlying conditions often occur together, 
the shared pathophysiology will be looked at a bit more closely. Uncontrolled systemic 
hypertension and elevated blood glucose levels can lead to increased glomerular wall 
stress, direct endothelial cell damage, and renal vasodilation. These insults result in 
structural and hemodynamic changes to the kidneys which cause the compensatory 
mechanisms above to occur. These changes, along with long-term intraglomerular 
hypertension and increased strain on the microvasculature cause cytokine release, such as 
transforming growth factor-beta, which result in further kidney injury. The end result of 
this pathogenesis is a histological manifestation known as focal segmental 
glomerulosclerosis, ultimately ensuing clinical signs and symptoms of disease.  
 
Complications of chronic kidney disease 
The kidneys perform several important functions for the human body. Other than filtering 
blood and removing wastes, the kidneys also play a role in fluid and electrolyte balance, 
acid-base homeostasis, blood pressure regulation, and producing hormones vital for red 
blood cell production and bone and mineral metabolism. Because the kidneys play such a 
vital role in so many body processes, several complications can arise when an individual 
has chronic kidney disease. These complications occur at different stages of the disease 
course. Below is a table summarizing some of the major complications of CKD. Some of 
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these complications will be discussed in further detail below because the management of 
these problems can have a direct effect on disease progression.  
Table 3. Complications of CKD. 
System  Complication 
Water Balance Volume overload 
Electrolytes Hyperkalemia  
Acid-Base Metabolic acidosis 
Bone and Mineral Hyperphosphatemia, secondary parathyroidism, vitamin D 
deficiency  
Hematological  Anemia 
Cardiovascular Hypertension, cardiovascular disease 
Lipid Metabolism Dyslipidemia 
 
 One complication that deserves further attention is the acid-base disturbance that 
occurs in CKD; metabolic acidosis. During the early stages of the disease the kidneys are 
able excrete enough titratable acid with the remaining nephrons present, however, as the 
GFR declines to stage 3 and lower, the kidneys are no longer able to remove a sufficient 
amount of acid from the body. Patients who have CKD with a metabolic acidosis have 
been shown to have an association with increased mortality and faster disease 
progression.
7,8
 Current dietary guidelines recommend treating metabolic acidosis in CKD 
patients when the serum bicarbonate falls to <22 mEq/L with Na
+
-based alkali therapy.
9
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This has been shown to be renal protective and slow the disease course, making the 
treatment of this complication imperative for disease management. 
 A second important complication that occurs in CKD is hyperphosphatemia. The 
retention of phosphorus begins early in chronic kidney disease, while evident 
hyperphosphatemia becomes more severe in stages 3-4 of the disease course. 
Hyperphosphatemia is one of the initial triggers that leads to the bone and mineral 
disorders that occur in CKD. This occurs because of two underlying mechanisms. In the 
early stages of CKD the remaining nephrons available are able to maintain phosphate 
excretion through increased tubule reabsorption, mediated by fibroblast growth factor 23 
(FGF23). However, through a variety of complex feedback loops involving several other 
hormones and electrolytes between the kidneys, intestines, bones, and vascular system, 
phosphate levels slightly rise. As GFR continues to decline more phosphate is retained, 
which further contributes to the other hormonal and electrolyte imbalances seen in bone 
and mineral disorder. Current guidelines recommend dietary phosphate restriction to .08-
1.0 g/kg/day, followed by the use of phosphate binders when diet restriction is no longer 
adequate. Treatment is guided by close monitoring of serum values. Hyperphosphatemia 
has been shown to increase mortality in chronic kidney disease
10
, which makes the 
treatment of this complication vital for CKD management. 
 
Measuring disease progression and severity 
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Once an individual is diagnosed with chronic kidney disease, the next most important 
step is to determine the degree of abnormal kidney function and how rapidly the disease 
is progressing. Nephrologists use several parameters including estimated glomerular 
filtration rate, urinary markers and sediment, and serum markers to evaluate the kidneys. 
All of this data will be evidence for how much kidney dysfunction is present, how far the 
disease course has progressed, and manifestations of any complications. As mentioned 
before, two important parameters are eGFR and urine albumin. 
 The glomerular filtration rate is the sum of the filtrating ability of all viable 
nephrons. Therefore, an eGFR gives a rough measure of how well the kidneys are 
filtering the plasma and the number of properly function nephrons. GFR can be variable 
from person to person, as it is affected by age, weight, race, serum markers, and body 
composition. Because so many factors can affect an eGFR, estimation equations have 
been developed that utilize demographic and clinical variables to make a more accurate 
estimation of GFR. While several estimation equations exist, the two most common are 
the MDRD and CKD-EPI equations. The limitations and advantages of both of these 
estimation equations will be discussed in more detail in the methods section. 
 The other method for assessing kidney function and injury is by measuring serum 
markers and urinary sediment. These act as clinical predictors for both the extent of 
nephron injury and acceleration of progression. Blood pressure should always be trended, 
as normal blood pressures have been associated with the preservation of GFR.
11
 The 
amount of proteinuria present should also be monitored. Higher levels of urinary protein 
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excretion have been associated with a more rapid decline in GFR
12
, while a reduction in 
proteinuria has been shown to slow the progression of renal disease.
13
 A metabolic panel 
will indicate the presence of any electrolyte imbalances, including abnormalities with 
sodium, potassium, phosphate, and calcium, while also unveiling the presence of any 
acid-base disturbances with serum bicarbonate. This panel will also show serum levels of 
BUN and creatinine which are indirect markers of kidney function, as these variables are 
included in GFR estimation equations. Lipid levels, including LDL-cholesterol and HDL-
cholesterol will be routinely checked as well. Finally, a complete blood count will unveil 
the presence of anemia. 
 
Prognosis of chronic kidney disease 
 The prognosis of chronic kidney disease is influenced by several different factors, which 
makes the disease course highly variable among individuals. The rapidity of disease 
progression is influenced by the underlying cause of kidney injury, presence of 
comorbidities, socioeconomic status, genetics, response to treatment, and ethnic 
background. Some patients will remain asymptomatic with a stable GFR for their entire 
life, while others will have a more rapid decline and several disease sequelae with 
eventual progression to end-stage renal disease.  
 According to the USRDS, the current mortality rate for individuals with CKD 
after being adjusted for age, race, and sex is 113 deaths per 1,000 patient years at risk.
4
 
Currently, the transition from an eGFR of >60 mL/min/1.73m
2
 to <60 mL/min/1.73 m
2
 is 
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0.5 percent per year, while the transition from an eGFR of 15-60 mL/min/1.73m
2
 to end-
stage renal disease is 1.5 percent per year. The Multiple Risk Factor Intervention Study 
showed that a combination of low eGFR and proteinuria was associated with a significant 
increased risk of disease progression versus either variable alone.
14
 Current life 
expectancy of patients over 50 with a normal eGFR and ACR is 35.2 years. An eGFR of 
<60 mL/min/1.73m
2
 is associated with a reduction in life expectancy of 5 years, while an 
ACR of >30 mg/g is associated with a reduction of 5.8 years. When both variables are 
present together, life expectancy drops by 11.8 years.
4
 
 CKD is also an independent risk factor for cardiovascular disease. Cardiovascular 
disease among individuals with chronic kidney disease results in death more than actual 
progression to end-stage renal disease.
15
 In patients aged 66 and older, the prevalence of 
cardiovascular disease is 66.8%, while only 43.1% in patients who do not have CKD. 
Chronic kidney disease and cardiovascular share a close and complex relationship in part 
due to the shared similarities in pathophysiology, as well as the overlap of several 
important risk factors. A decline in eGFR and increase in ACR increase the risk for 
cardiovascular disease. Patients with CKD have a higher risk of death from 
cardiovascular disease versus the need for renal replacement therapy. This makes the 
prevention and management of cardiovascular disease critical for patients with CKD. 
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Chronic kidney disease and healthcare costs 
According to the Center for Disease Control, chronic kidney disease is the ninth leading 
cause of death in the United States. From 2013 to 2014, there was a decrease in 
hospitalizations among patient with CKD by 7.4%.
4
 Hospital readmission rates were also 
slightly decreased from 2013 to 2014, with a readmission rate of 21.4% for CKD 
patients. Although the trend of hospitalizations and readmissions is decreasing, the 
burden of chronic kidney disease is still seen in healthcare costs. Both CKD and ESRD 
are very expensive to treat, and these two conditions alone represent 25% of the Medicare 
budget.
16
 According to the most recent numbers from the National Kidney Disease 
Education Program, CKD costs $57.5 billion in health care costs in the United States.
17
 
This makes efficient and proper management crucial not only for the individual affected 
by chronic kidney disease, but for the healthcare system overall. 
 
Chronic kidney disease and diet 
While no single diet has been proven with clinical certainty to be the sole best for chronic 
kidney disease, there are several guidelines that have showed some promise in affecting 
clinical outcomes in patients with CKD. Diet can be very challenging for these 
individuals. Eating in excess can result in drastic changes to volume status, lead to the 
buildup of waste products from protein degradation, and cause electrolyte imbalances 
including changes in sodium, hyperkalemia, and hyperphosphatemia. Eating too little can 
lead to anorexia, muscle wasting, and malnutrition. This makes developing an optimal 
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diet vital for disease management. Dietary changes are initiated in patients with an eGFR 
of <60 mL/min/1.73m
2
. Certain dietary changes have been shown to slow disease 
progression and alleviate complications. Current dietary recommendations include 
protein restriction of <0.8 g/kg, sodium intake <2 g/day for hypertensive, proteinuric, or 
volume overload patients, and potassium and phosphorus intake guided by lab values. 
 
What is a plant-based diet? 
A whole-food, plant-based diet is a diet centered on whole, unrefined, or minimally 
unrefined plants. This includes fruits, vegetables, starchy vegetables, whole grains, and 
legumes. 
 
Existing research 
 
Protein source and GFR progression 
While existing data shows that protein amount can affect GFR progression, fewer studies 
look into how the source of protein affects GFR's progression. One study showed that 
higher red meat intake increased the risk of CKD progression to ESRD.
18
  An 11 year 
prospective cohort study done by Knight et al. looked at how different protein sources 
over time affected renal function and decline in individuals with normal and mild renal 
insufficiency. 1,642 women, aged 42-68, who were participants in the Nurses' Health 
Study gave blood samples in 1989 and 2000. They were also using semi-quantitative food 
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frequency questionnaires that were able to determine protein intake and by what source. 
Women with normal renal function, which was defined as GFR >80 mL/min/1.73m
2
, 
showed no association with increased protein intake, regardless of the source, and renal 
function decline. However, women with mild renal insufficiency, defined as a GFR 
within 55-80 mL/min/1.73m
2
, a significant association was found between protein intake 
and GFR decline. For every 10g increase in total intake, GFR declined by -1.69 mL/min 
([CI], -2.93 to -0.45). Further, higher intake in animal protein resulted in an even greater 
decline by -1.21 mL/min ([CI], -2.34 to -0.33).
19
 High protein intake, in particular high 
animal protein consumption, was associated with acceleration in renal function decline in 
women with mild renal insufficiency. 
A prospective, randomized, controlled trial was done by Garneata et al. to 
compare a conventional low-protein diet with a vegetarian low-protein diet supplemented 
with ketoanalogues. The adult patients had stage 4 CKD and ACR of <1000 mg/g. 207 
patients were randomly assigned to a group receiving 0.3g/kg/day of vegetable protein 
with ketoanalogue  supplementation or a conventional low protein diet of 0.6g/kg/day of 
protein from other sources for 18 months. Patients in both groups received nutritional 
counseling and monthly monitoring. Measured parameters included the need for renal 
replacement therapy or >50% decline in eGFR. GFR was measured monthly. Of the 207 
individuals, 55 reached the measured end-points. Of this 28%, 42% were in the 
conventional low-protein diet, while only 13% from the low vegetable protein 
(P<0.001).
20
 Upon Kaplan-Meier analysis, the cumulative probability to reach one of 
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these endpoints was 12% for the vegetable protein group, compared to 33% for the 
conventional protein group.
20
 The median eGFR was similar in both diet groups at any 
time during the 15 months, however, at the end of the study the vegetable protein group 
showed a slower decline in eGFR overall. This suggested that a vegetable based protein 
diet with supplemental ketoanalogue could slow CKD progression and delay the need for 
dialysis. 
 
Soy protein for treating albuminuria 
Treating albuminuria has been shown to slow the progression of chronic kidney disease, 
which makes this another target for dietary intervention. One way this has been done is 
by protein moderation, which has been shown to reduce proteinuria. However, there are a 
few studies that show certain protein sources, specifically soy-based protein sources from 
plants, can further reduce albuminuria in CKD patients. Further, one study showed that a 
diet high in animal fat intake and two or more servings of red meat per week may 
increase the risk for microalbuminuria
21
, while another study showed a diet high in whole 
grains, fruits and vegetables was shown to be associated with lower albuminuria.
22
 
Teixeira et al. performed a 7-month crossover study design with 34 individuals with type 
2 diabetes mellitus, age 53-73 years, with albuminuria <2000 mg/24-h. In this study 
subjects served as their own controls. Individuals would consume a diet consisting of 
0.5g/kg/day of either soy or casein protein for 8-week time periods, while all underwent a 
4-week washout period of a 1.0g/kg/day diet of non-soy protein. Subject met with 
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registered dieticians every 2 weeks during the study to receive their protein powder 
isolate and review diet journals. Measured outcomes included urine albumin to creatinine 
ratio, LDL-cholesterol, HDL-cholesterol, and creatinine clearance. This study found 
significant reduction in ACR for the soy protein group (212.6±139.6 versus 192.3±122.7, 
P<0.0001), while the casein group found an increase in ACR (146.4±88.8 versus 
182.4±102.2, P=0.0020).
23
 Changes in CrCl were found to be not significant in both 
groups. This study concluded that soy protein versus casein protein significantly reduced 
albuminuria in patients with type 2 diabetic nephropathy. 
Another study by Azadbakht et al. did a similar crossover, randomized clinical 
trial on 14 patients (10 men, 4 women) with type 2 diabetes with nephropathy. All the 
subjects had proteinuria ranging from 300-1000 mg/g, creatinine between 1-2.5 mg/dL, 
and a BUN between 20-40 mg/dL. Patients followed a diet of 0.8g/kg/day of 70% animal 
protein and 30% plant protein for 7 weeks, underwent a 4-week washout period, and then 
consumed a diet consisting of 0.8g/kg/day of 35% soy protein, 30% vegetable protein, 
and 30% animal protein. The study resulted in significant reductions in proteinuria and 
BUN (P<0.001), as well as total cholesterol (P<0.01) and triglycerides (P<0.02), thus 
concluding a diet consisting of soy and plant protein can improve kidney function in 
patients with diabetic nephropathy.
24
 Azadbakht et al. followed this study up with a 
randomized, clinical trial among 41 diabetic patients with nephropathy. The inclusion 
criteria was the same as the previous trial, only this time patients followed the two diets 
for 4 years total. Parameters were measured at baseline, and at the end of each year. A 
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significant reduction in proteinuria was seen in the soy protein group (667±58 versus 
513±39, P<0.01), while the animal protein group saw an increase in proteinuria (691±71 
versus 725±81, P=0.1).
25
 While GFR was preserved and remained stable, it did so in both 
groups and was found not to be significant. A significant change was also found in 
fasting blood glucose levels in the soy group (141±55 versus 121±42, P<0.03) and total 
cholesterol (255±48 versus 201±5, P<0.01), while both outcomes increased in the animal 
protein group. The conclusion was made that longitudinal soy protein consumption 
improved indexes of kidney injury, provided better blood glucose control, and reduced 
cardiovascular risk better than an animal protein diet. 
 
Fruits and vegetables for treating metabolic acidosis  
As mentioned above, the presence of a metabolic acidosis in CKD patients has been 
shown to cause a more rapid decline in GFR and is associated with higher mortality, 
while treating this complication has been shown to slow disease progression. This makes 
metabolic acidosis an important target for dietary management for individuals with CKD. 
Current gold standard treatment is initiating sodium bicarbonate therapy when serum 
bicarbonate falls <22 mEq/L. However, this added dietary sodium may worsen 
hypertension and make volume control more difficult. Further adding to the problem is 
that current societal diets are high in acid-producing foods, including meats and 
processed foods. Two studies were done to see how a diet focused more on base-
producing foods like fruits and vegetables would affect metabolic acidosis. These two 
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studies (all done by Goraya et al.) were randomized, controlled studies on individuals 
with different stages of hypertension-associated nephropathy.    
 The first study was done on 76 individuals with CKD stage 4 hypertension-
associated nephropathy. Other inclusion criteria included having a plasma bicarbonate 
<22 mM, serum potassium of <4.6 mEq/L, non-malignant hypertension, no diabetes or 
cardiovascular disease, and 18 years of age or older. Individuals underwent a 6-month 
blood pressure control reduction protocol with an end goal of systolic blood pressure 
<140 mmHg. Of the 76, 35 received oral sodium citrate at 1.0 mEq/kg/day, while the 
other 36 received fruits and vegetables, free of charge from a food bank. Measured 
outcomes included urine net acid excretion, plasma bicarbonate, serum potassium, urine 
albumin, systolic blood pressure, and potential renal acid load. These were measured at 
baseline and one year. Plasma bicarbonate was higher in the HC03 group (21.2±1.3 
versus 19.5±1.5, P<0.01) and the F+V group (19.9±1.7 versus 19.3±1.9, P<0.01). 
Systolic blood pressure was lower in the F+V group (131.7±3.3 versus 136.3±4.8, P< 
0.01), but not the HC03 group (136.0±4.4 versus 136.1±4.7, P=0.88). Potential renal acid 
load was also much lower in the F+V group (39.6±10.4 versus 62.1±6.8, P<0.01), while 
unchanged in the HC03 (59.3±6.3 versus 59.0±6.5, P=0.28).
26
 The serum potassium 
levels remain unchanged for both groups from baseline and did not induce hyperkalemia. 
Baseline value for urine albumin were not different for both groups, and 1-year compared 
with baseline was lower for both groups (P<0.01). This study was able to conclude that 
one year of dietary acid reduction using fruits and vegetables was able to improve 
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metabolic acidosis, reduce kidney injury, did not induce hyperkalemia, while reducing 
systolic blood pressure. 
The second study conducted similarly compared F+V to oral sodium bicarbonate 
for treating metabolic acidosis, while also exploring its affect on GFR, urinary indices of 
kidney injury, and urinary angiotensinogen levels. This study had 108 individuals, all 
with CKD stage 3 hypertension-associated nephropathy. Other inclusion criteria included 
a serum bicarbonate of 22-24 mM, presence of macroalbuminuria, nonsmokers, and no 
cardiovascular disease or diabetes. Patients were divided into 3 groups. Group 1 received 
F+V prescribed by a registered dietician, group 2 received oral sodium bicarbonate at a 
dose of 0.3 mEq/kg/day, while group 3 received no treatment based on current care 
guidelines. Measured outcomes included plasma bicarbonate, serum potassium, blood 
pressure, urine albumin to creatinine ratio, urine angiotensinogen II to creatinine ratio, 
cystatin-C eGFR, and creatinine eGFR. Outcomes were measured at baseline and 36 
months. The serum bicarbonate was higher in the F+V group (23.9±0.6 versus 23.0±0.5, 
P<0.001) and in the oral sodium bicarbonate group (23.1±0.6 versus 24.0±0.6, P<0.001), 
while decreasing in the usual care group. The F+V group and alkali therapy group both 
had significant preservation in eGFR progression when compared to the usual care group. 
Measured 
Outcomes 
Usual 
Care 
Fruits and 
Vegetables 
Oral 
Sodium 
Bicarbonate 
P-
Value: 
3 
Groups 
Usual 
Care 
Fruits and 
Vegetables 
Oral 
Sodium 
Bicarbonate 
P-
Value: 
3 
Groups 
Creatinine 42.6±7.6 42.3±7.1 42.6±7.0 0.99 28.8±7.3 36.9±3.7 35.2±6.9 <0.01 
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eGFR 
Cystatin-C 
eGFR 
39.5±.8 39.4±6.4 39.6±6.6 0.99 26.6±7.0 34.3±6.4 32.7±6.7 <0.01 
 
As in the previous study, the F+V group was the only group with significant blood 
pressure reduction (165.1±10.1 versus 135.7±4.5, P<0.001). All groups showed a decline 
in ACR, with F+V having the biggest decrease (318±71 versus 242±56, P<0.01), 
followed by the oral bicarbonate group (317±72 versus 262±62, P<0.01). Urinary 
angiotensinogen II levels also decreased in both the F+V group (35.5±5.4 versus 
32.1±5.2, P<0.01) and oral bicarbonate group (35.4±5.7 versus 32.0±5.3, P<0.01), but not 
the usual care group.
27
 This study was able to conclude that 3 years of dietary acid 
reduction with fruits and vegetables improved metabolic acidosis, reduced systolic blood 
pressure, reduced urinary kidney injury, and preserved eGFR in CKD stage 3 patients. 
The data also demonstrates F+V are effective in mitigating AII's contribution to 
nephropathy. 
 
Plant protein and the treatment of hyperphosphatemia 
As CKD advances, phosphate levels rise in the blood as the kidney is unable to filter out 
the excess phosphate ions. These patients begin to develop hyperphosphatemia, which 
increases a patients risk for cardiovascular disease and fractures.
28,29
 Current treatment is 
guided by patient specific lab values. Because of the implications this complication has 
on quality of life and survival, diet has potential value as a form of management. Current 
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dietary recommendations are <800 mg/d of phosphorus in the diet. Plant-based foods are 
known to have less bioavailable phosphorus than meat, making a vegan diet particularly 
beneficial in this situation. Moe et al. conducted a crossover study on 9 patients with an 
eGFR of 25-40 mL/min/1.73m
2
. These patients also had a normal serum phosphorus 
levels and were not on any phosphate binding medications. Patients were randomized to 
receive a diet of grain and soy based protein or animal and dairy based protein for 1 
week. Each diet consisted of 20% protein and 800 mg of phosphorus. Patients consumed 
each diet for 1 week, underwent a 4 week washout period, and then consumed the 
opposing diet. Blood and urine measurements were taking at baseline and the end of each 
of the two test weeks. Outcomes measured included plasma phosphorus, plasma FGF23, 
and urine 24-h phosphorus excretion. The grain protein diet saw a statistically significant 
decrease in serum phosphorus (3.5±0.6 versus 3.2±0.5, P<0.02) and serum FGF23 
(84±65 versus 61±35, P<0.008) compared to the meat/dairy protein diet, which saw a rise 
in both phosphorus (3.5±0.6 versus 3.7±0.6) and FGF23 (72±39 versus 101±83). The 
grain protein group also saw a decrease in urinary phosphorus excretion, however, it was 
not found to be a significant decrease when compared to the animal protein group 
(778±190 versus 416±233, P<0.07).
30
 This study concluded that a plant-based protein 
source can have a different effect on phosphorus homeostasis compared to animal-based 
protein when managing CKD patients. 
Moorthi et al. followed this study up with a 6-week long controlled trial on 13 
individuals (7 female, 6 male), with an eGFR between 15-60 mL/min/1.73m
2
. The other 
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inclusion criteria was similar to the previous study. Patients were instructed to consume 
their regular diet for 2 weeks, at which point they gave blood and urine samples which 
was used as baseline data. The participants were then provided a diet consisting of 
0.84g/kg/day of protein (70% from plant sources, 30% from meat/dairy) and 0.8-
1.0g/kg/day of phosphorus. Subjects met weekly to pick up prepared meals and meet with 
a dietician to discuss compliance and receive dietary education. At the conclusion of the 
4 weeks, urine and blood samples were taken again, assessing serum phosphorus and 
FGF23 and 24-h urinary phosphorus. The result showed a significant decrease in urinary 
phosphate excretion (830±224 versus 597±233, P<0.001).
31
 There was also a decrease in 
serum phosphorus and FGF23, but this decrease was not found to be statistically 
significant. This demonstrated a diet containing 70% protein from plant source is an 
effective way of lowering urinary phosphorus excretion, thus providing a potential 
alternative phosphate binding drugs. 
 
Plant protein and all-cause mortality in chronic kidney disease 
Plant protein sources and a plant-based diet has been shown to preserve GFR, reduce 
proteinuria, treat metabolic acidosis, and reduce serum phosphorus levels in patients with 
CKD. This type of diet has also shown to improve serum lipid levels, reduce blood 
pressure, and provide blood glucose control, which are all additional risk factors for CKD 
progression. Chen et al. did an observational study that looked at plant protein intake and 
its association with all cause mortality in chronic kidney disease patients. This 
 26 
 
observational study looked at 14,866 patients from the NHANES III who were 20 years 
or older. During this NHANES III survey, patients underwent dietary interviews 
assessments which looked at how much of the participants diet was derived from plant or 
animal sources. This observational study included all the participants who had no dietary 
data missing. The subjects were stratified into two groups based of eGFR, group 1 being 
>60 mL/min/1.73m
2
, while group 2 was <60 mL/min/1.73m
2
. Participants were adjusted 
for age, sex, race, smoking history, physical activity, and caloric intake. The data showed 
that every 33% increase in plant protein ratio intake had a statistically not significant risk 
for death in the eGFR >60 group (HR, 0.87; [CI], 0.74-1.03), while the eGFR <60 group 
showed a significant lower risk for death (HR, 0.81; [CI], 0.66-0.99).
32
 When these 
groups were further adjusted for body mass index, hypertension, stroke, diabetes, 
myocardial infarction, and congestive heart failure there was an even stronger association 
with increased plant protein intake ratio and lower mortality in the eGFR <60 group. This 
suggests that for a given protein intake, higher proportion of plant sources is associated 
with lower mortality in CKD patients.
32
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METHODS 
Study design 
The study is a 36-month  randomized-controlled trial comparing the conventional 
recommended diet versus a plant-based diet for patients with chronic kidney disease. 
Individuals with CKD stage 3 (eGFR 30-59 mL/min/1.73m
2
) will randomly be assigned 
to receive a traditional diet prescribed for CKD patients, or a plant-based diet. The 
specifics of each diet will be discussed below. The primary outcome measured will be 
change in eGFR. Secondary outcomes being measured will include urine albumin, serum 
bicarbonate, serum phosphorus, and need for dialysis.  
 
Study population and sampling 
Patients participating in this study will be chosen from Boston Medical Center outpatient 
nephrology clinics. These individuals will be selected based off the inclusion and 
exclusion criteria that will be outlined below. After patients are selected they will 
continue to resume their usual routine medical care at their respective outpatient clinics. 
After looking at a previous study that showed a meaningful change in GFR over time to 
be -4.8 ± 3.7 mL/min/1.73m
2
 was associated with increased mortality
33
, it was 
determined that a sample size of 40 in each group, using a t-test sample size calculation, 
was needed to achieve an 80% power and an alpha of 0.05 to detect a ≥50% reduction in 
the change in GFR over time. This study will aim for a sample size of 50 to allow for a 
potential 25% dropout rate over the 36 months.  
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 Study subjects will be chosen based off the following inclusion criteria: (1) CKD 
stage 3 with an eGFR of 30-59 mL/min/1.73m
2
; (2) history of hypertension that is 
currently well controlled as evidence by a systolic blood pressure <150 mmHg; (3) 
history of non-insulin dependent type 2 diabetes mellitus that is currently well controlled 
as evidence by a hemoglobin A1c <9%; (4) urine albumin-to-creatinine ratio of 30-1000 
mg/g; (5) a decline in GFR >4.8 mL/min/1.73m
2
 in the previous year; (6) metabolic 
acidosis defined as a serum bicarbonate >22 mEq but <24 mEq and not taking oral 
sodium based alkali therapy; (7) serum phosphorus levels >4.0 mg/dL but <4.5 mg/dL 
and not taking phosphate binders; (8) nonsmokers based off no tobacco use for over one 
year; (9) no hospitalizations related to chronic kidney disease for the previous year 
leading up to the study; (10) no history of cardiovascular disease; (11) ability to 
understand and follow through on the dietary interventions; and (12)  >18 years of age 
but <65 years of age. Exclusion criteria include; (1) chronic kidney disease caused by any 
genetic disorders, congenital anomalies, autoimmune disease, glomerulonephritis, 
vascular disease, such as renal artery stenosis, primary glomerular disease, or 
tubulointerstitial disease; (2) history of cardiovascular disease, including previous stroke, 
myocardial infarction, or heart failure; (3) acute kidney injury within the previous year of 
the study; (4) plasma potassium >4.5 mEq/L; and (5) unable to tolerate a plant-based diet 
for either health or socioeconomic reasons.  
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Treatment (or intervention) 
Subjects in this study will be randomly allocated into one of two groups. Subjects in 
group 1 will receive the conventional recommended diet for CKD patients, while subjects 
in group 2 will receive a plant-based diet. Both diets will be isocaloric at 35 kcal/kg/day. 
Of the caloric intake, 60% will be from carbohydrates, 30% from fats, and 10% from 
protein. Each diet will provide 0.8 g/kg/day of protein, 0.8-1.0 mg/kg/day of phosphorus, 
<3 g of potassium,  and <2 g of sodium. The conventional diet will consist of animal and 
dairy sources for 70% of its protein, while the other 30% will come from plant sources. 
The plant-based diet will consist exclusively of whole grains, legumes, fruits, and 
vegetables. 
 
Study variables and measures 
The primary outcome being measured is change in glomerular filtration rate, which will 
be done using the CKD-EPI estimation equation because it has been shown to be just as 
accurate as the MDRD equation
34
 and is more accurate for risk prediction of adverse 
outcomes for CKD patients.
35
 This CKD-EPI equation utilizes serum creatinine, sex, 
race, age, and body surface adjustment to calculate GFR, however, a more accurate 
version of this equation can be used that makes use of another serum marker; cystatin C. 
The CKD-EPI combination equation using both serum creatinine and cystatin C has been 
shown to be more accurate in predicting GFR
36
, therefore, this version of the equation 
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will be used in the study. Secondary outcomes that will be measured are urinary albumin 
levels, plasma bicarbonate and phosphorus, and need for dialysis.  
 
Recruitment 
Potential study participants will be recruited from Boston Medical Center outpatient 
nephrology clinics. Patients will be contacted to participate in this study in two ways. 
Some will be directly approached in the waiting rooms of outpatient clinics, explained the 
study and its design, and asked to give consent to review their electronic medical record 
to see if they fit the criteria to participate in the study. Other potential candidates will be 
contacted by telephone and will similarly be explained the study and asked for consent to 
evaluate the electronic medical record. After individuals are found to meet the inclusion 
and exclusion criteria, they will once again be contacted and asked to participate in the 
study. Once an individual agrees to both participation and randomization, they will be 
matched for baseline glomerular filtration and baseline urine albumin with another study 
subject and undergo randomization. 
 
Data collection 
Data will be collected at the Boston Medical Center laboratory located in the Shapiro 
Building. This will include both urine samples and blood draws. Baseline measurements 
will be collected on the first day of the trial before any dietary intervention has begun. 
The collections will be done after 8-hour fasting beginning the night prior. After initial 
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urine and blood samples are obtained, participants will then begin following their 
respective diets. The samples collected will be used to determine eGFR, urine albumin 
levels as a urine albumin-to-creatinine ratio, and serum bicarbonate and phosphorus. The 
same measurement tools, assays, and lab will be used to obtain the data for each sample 
collected. Samples will then be collected every 4 months, ± 1 week to allow for patient 
convenience, in a similar fashion for the 36 months of the study, equating to a total of 10 
lab visits per participant for the duration of the trial. After the final measurements are 
calculated, the data will be transferred into an Excel document that will keep track of 
each individual's data. At the conclusion of the trial, this compiled data will be used to 
perform the statistical analyses discussed below.   
 
Data analysis 
Subject characteristics at the beginning of the study, including age, race, sex, eGFR, 
albumin-to-creatinine ratio, serum bicarbonate, and serum phosphorus, will be tabulated 
by mean and standard deviation. A t-test will be done to compare baseline characteristics 
between the two groups. The primary outcome being measured is change in eGFR. 
Secondary outcomes being measured include urine albumin levels, serum bicarbonate, 
and serum phosphorus. The changes from baseline to the conclusion of the trial will be 
described as mean and standard deviations and compared using a t-test. In order to 
evaluate other variables that may be related to the primary outcome, multivariate analysis 
will be done to adjust for age, race, and sex. Stratified analysis will also be done to 
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control for any factors determined to be confounding. A P-value <0.05 indicates 
statistical significance. Graphs will be included to give a visual representation of the data. 
 
Timeline and resources 
During the initial recruitment phase of the trial, both physicians and medical or physician 
assistant students will review the electronic medical records and contact potential 
candidates for the trial based on the inclusion and exclusion criteria discussed above. 
After participants give consent to be in the study, they will have two follow-up 
appointments to attend. The first will be with one of the primary co-investigators of the 
study, a nephrology physician at Boston Medical Center. This physician will go over 
specific aims and details of the trial with the participants individually and answer all 
questions. After this meeting, the subject may resume seeing their respective 
nephrologists in the BMC system, who will all be aware of the trial that is taking place. 
 The second appointment participants will attend is with a registered dietician with 
a specialization in kidney disease. Here they will receive education on the particular diet 
they have been randomized too. Participants will also receive a food diary, where they 
will record when and what they eat. Participants in both groups will receive food stamps 
that will allow them to pickup fresh produce, free of charge, at participating community 
food banks. This will provide the 30% of plant-sourced protein for the conventional diet 
group, while providing the same amount of produce for the plant-based group. 
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 After the conclusion of these two appointments participants will then schedule a 
time to have their baseline urine samples and blood draws done. After the completion of 
the labs, patients will begin their respected diets that same day. Subjects will record in 
their food journals daily, and meet with the renal dietician monthly to review them, have 
questions answered, and ensure diets are being followed. Participants will also follow-up 
with their nephrologists every 4-6 months as part of their routine care. Patients will have 
lab data obtained every 4 months. This resulted data will be sent directly to a statistician 
who will manage the Excel document. A group of unblinded statisticians will perform 
interim analysis comparing both groups as a measure of safety to make certain neither 
group is being put at unnecessary risk. At 36 months final data will be gathered and the 
trial will be complete. 
 
Institutional Review Board 
 An application detailing the protocol of the study will be submitted for full review to the 
Boston University Medical Campus Institutional Review Board. IRB approval will be 
obtained prior to the recruitment of study participants.  
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CONCLUSION 
Discussion 
This study would be the first of its kind that compared a conventional CKD diet with a 
completely plant-based diet that looked at glomerular filtration rate as the primary 
outcome. Previous studies that have been done that looked at plant-sourced food and 
CKD have either been observational studies, control trials that used study subjects as 
their own controls, or looked at other measured parameters as the primary outcome. This 
study also has strengths in the population being sampled by taking patients with the most 
prevalent stage of chronic kidney disease, and those with the two most common 
comorbidities. 
   While this study does have strengths, there are still notable limitations. The 
sample size is small, and would need to be studied on a larger scale to further validate the 
results. This study also only addresses one stage of chronic kidney disease, and it will 
still remain unknown if this diet may provide the same potential benefits or harm at 
earlier and later stages of the disease course. The smaller sample size and specific 
inclusion and exclusion criteria may limit the generalizability of the study, specifically 
for those with different comorbidities, past medical history, and patients at higher risk of 
adverse outcomes. 
 Additionally, this study has several anticipated obstacles. The dietary 
interventions being studied require strict adherence to prove the results. Adopting a new 
diet can be very challenging for patients and requires lots of modification to their 
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previous lifestyle. This alone may cause patients to exit the trial. The study also calls for 
close and regular follow-up. This could become very time consuming for participants, 
and may even result in patients leaving the trial as well. If adopting either diet is found to 
be a big problem for patients, they may need further education on how to apply these 
changes to their daily lives.  
 
Summary 
While no optimal diet exists when managing patients with CKD, there are guidelines and 
recommendations that have become accepted by nephrologists. While some studies exist 
that support these guidelines, other studies have been done that demonstrated no benefit 
to these recommendations at all. Further, these current standards fail to address whether 
the source (plant versus animal) has any affect on chronic kidney disease. 
 The research above suggests that a plant-based diet may have an overall positive 
effect on several parameters used to assess the severity, prognosis, and risk of mortality 
for patients with chronic kidney disease. This includes reducing albuminuria as a sign of 
kidney injury, treating metabolic acidosis, managing electrolyte abnormalities such as 
hyperkalemia and hyperphosphatemia, and recuing all-cause mortality. Further, this type 
of diet may also aid in blood pressure lowering and blood glucose control, which are both 
integral parts of CKD management. Most importantly, a plant-based diet may actually 
slow the progression of chronic kidney disease by delaying the decline in GFR. 
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 The proposed study design will compare a plant-based diet with a conventional 
diet and its affect on the glomerular filtration rate over time in patients with chronic 
kidney disease. This may help identify any gaps that exists in current dietary 
recommendations, and may even shift how patients with CKD are educated on the food 
they consume on a daily basis. This study could demonstrate how the source of food, 
rather than amount, can impact patients with chronic kidney disease.    
 
Clinical and/or public health significance 
For patients with chronic kidney disease, there is no cure. Current management is aimed 
at slowing the rate of GFR decline, treating associated comorbidities, and addressing 
complications as they arise. Recommendations are also made regarding lifestyle 
modifications, specifically diet. If a plant-based diet is found to delay the progression of 
chronic kidney disease while improving additional disease complications, patients may 
see an overall improvement in quality of life and reduction in symptoms that affect their 
daily lives. This would also potentially reduce the amount of medications they need to 
take, as well as delaying the time to dialysis or renal replacement therapy. Individual 
patients would not be the only ones benefitting from this diet. The healthcare costs for 
patients with chronic kidney disease may show a decline as well, especially if the time to 
dialysis and need for medications is delayed. Overall, adopting a plant-based dietary 
lifestyle may become something that patients with chronic kidney disease can do each 
day in order manage their disease, slow its progression, and improve their quality of life.  
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